Results 11 to 20 of about 728,641 (268)

Core Percolation on Complex Networks [PDF]

Physical Review Letters, 2012
As a fundamental structural transition in complex networks, core percolation is related to a wide range of important problems. Yet, previous theoretical studies of core percolation have been focusing on the classical Erdős-Rényi random networks with Poisson degree distribution, which are quite unlike many real-world networks with scale-free or fat ...
Yang-Yu, Liu, Endre, Csóka, Haijun, Zhou, Márton, Pósfai   +3 more
openaire   +4 more sources

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy

Frontiers in Oncology, 2021
The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as cetuximab, poses a challenging problem.
Hannah Zaryouh, Ines De Pauw, Hasan Baysal, Patrick Pauwels, Patrick Pauwels, Marc Peeters, Marc Peeters, Jan Baptist Vermorken, Jan Baptist Vermorken, Filip Lardon, An Wouters   +10 more
doaj   +1 more source

Emergence of core–peripheries in networks [PDF]

Nature Communications, 2016
AbstractA number of important transport networks, such as the airline and trade networks of the world, exhibit a characteristic core–periphery structure, wherein a few nodes are highly interconnected and the rest of the network frays into a tree. Mechanisms underlying the emergence of core–peripheries, however, remain elusive. Here, we demonstrate that
Verma, T., Russmann, F., Araújo, N. A.M., Nagler, J., Herrmann, H. J.   +4 more
openaire   +7 more sources

Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer

Cells, 2020
The concept of immunogenic cell death (ICD) has emerged as a cornerstone of therapy-induced anti-tumor immunity. To this end, the following chemotherapies were evaluated for their ability to induce ICD in non-small cell lung cancer (NSCLC) cell lines ...
Tal Flieswasser, Jinthe Van Loenhout, Laurie Freire Boullosa, Astrid Van den Eynde, Jorrit De Waele, Jonas Van Audenaerde, Filip Lardon, Evelien Smits, Patrick Pauwels, Julie Jacobs   +9 more
doaj   +1 more source

Integrating patient-reported physical, mental, and social impacts to classify long COVID experiences

Scientific Reports, 2023
Long COVID was originally identified through patient-reported experiences of prolonged symptoms. Many studies have begun to describe long COVID; however, this work typically focuses on medical records, instead of patient experiences, and lacks a ...
Keri Vartanian, Daniel Fish, Natalie Kenton, Benjamin Gronowski, Bill Wright, Ari Robicsek   +5 more
doaj   +1 more source

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies

Frontiers in Immunology, 2021
Cetuximab has an established role in the treatment of patients with recurrent/metastatic colorectal cancer and head and neck squamous cell cancer (HNSCC).
Hasan Baysal, Ines De Pauw, Hannah Zaryouh, Marc Peeters, Marc Peeters, Jan Baptist Vermorken, Jan Baptist Vermorken, Filip Lardon, Jorrit De Waele, An Wouters   +9 more
doaj   +1 more source

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma

Biomedicines, 2022
Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs, and is causally associated with asbestos exposure. Until recently, the first-line treatment consisted of a combination of chemotherapeutics that only
Sophie Rovers, Annelies Janssens, Jo Raskin, Patrick Pauwels, Jan P. van Meerbeeck, Evelien Smits, Elly Marcq   +6 more
doaj   +1 more source

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers

Antioxidants, 2023
Auranofin (AF) is a potent, off-patent thioredoxin reductase (TrxR) inhibitor that efficiently targets cancer via reactive oxygen species (ROS)- and DNA damage-mediated cell death.
Laurie Freire Boullosa, Jinthe Van Loenhout, Tal Flieswasser, Christophe Hermans, Céline Merlin, Ho Wa Lau, Elly Marcq, Marlies Verschuuren, Winnok H. De Vos, Filip Lardon, Evelien L. J. Smits, Christophe Deben   +11 more
doaj   +1 more source

Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model

Pharmaceutics, 2022
The antineoplastic activity of the thioredoxin reductase 1 (TrxR) inhibitor, auranofin (AF), has already been investigated in various cancer mouse models as a single drug, or in combination with other molecules.
Laurie Freire Boullosa, Jinthe Van Loenhout, Christophe Hermans, Ho Wa Lau, Céline Merlin, Elly Marcq, Farnaz Sedigheh Takhsha, Wim Martinet, Guido R. Y. De Meyer, Filip Lardon, Evelien L. J. Smits, Christophe Deben   +11 more
doaj   +1 more source

Rich-Cores in Networks

PLOS ONE, 2015
12 pages, 6 ...
Ma, A, Mondragon, RJ
openaire   +6 more sources